The $270M cash dividend creates a near-term floor for FULC shares. Traders should monitor the spread between current price and the implied value of the cash dividend plus the stub equity. Key catalysts: Fulcrum stockholder vote, HSR clearance, and S-4 effectiveness. The stub value of the ~5% stake in Slate's pipeline (lead candidate SLTE-1009) is highly speculative and will determine long-term upside.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 17 $3.84entry
- T+1 · 3mo ago +0.78%α +1.46% · $3.87
- T+5 · 3mo ago 0.00%α +1.19% · $3.84
- T+20 · 2mo ago −1.56%α +0.42% · $3.78
- T+60 · 7d ago −3.13%α −0.18% · $3.72
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Fulcrum Therapeutics (FULC) and Slate Medicines announced a definitive merger agreement in which Fulcrum will acquire Slate in an all-stock reverse merger. Fulcrum is valued at $31.3M and Slate at $350M, with a concurrent $245M PIPE led by Frazier Life Sciences. Pre-merger FULC stockholders will receive a special cash dividend of approximately $270M (subject to adjustment) and will own ~5% of the combined company, which will be renamed Slate Medicines and trade under the ticker SLTE. The deal is expected to close in Q4 2026.
Key Financial Metrics
Key Facts
- Fulcrum valued at $31.3M, Slate at $350M in all-stock merger
- $245M concurrent PIPE from Frazier Life Sciences, Forbion, RA Capital, and others
- Pre-merger FULC stockholders to own ~5% of combined company on a fully-diluted basis
- FULC stockholders to receive ~$270M special cash dividend (subject to adjustment based on net cash)
- Combined company to be renamed Slate Medicines, Inc. and trade under ticker SLTE
- Slate's management team to operate the combined company; Slate's board to control
- Expected closing in Q4 2026; subject to stockholder approvals, HSR clearance, and Nasdaq listing
- Slate's lead product candidate SLTE-1009 mentioned in forward-looking statements
Financial Impact
FULC stockholders to receive ~$270M cash dividend (~95% of current $285M market cap) plus a ~5% equity stake in the combined company; Slate valued at $350M with $245M PIPE providing cash runway into 2029
Risk Factors
- Deal may fail to close (requires Fulcrum stockholder approval, HSR clearance, Nasdaq listing)
- Cash dividend amount subject to downward adjustment based on Fulcrum's net cash at closing
- The 5% stub stake in the combined company has uncertain value given Slate's early-stage pipeline
- Termination fee of $10M payable by Fulcrum to Slate under certain circumstances
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (Primary) | 0001193125-26-353280 |
| Document: 0001193125-26-353280-index-headers.html | 0001193125-26-353280 |
| Document: 0001193125-26-353280-index.html | 0001193125-26-353280 |
| Document: 0001193125-26-353280.txt | 0001193125-26-353280 |
Track record
23 reports on FULC
5 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +7.71% at T+60 after the Jul 15, 2026 report. 6 of 6 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $3.72 Now $3.71 −0.27% settles Nov 18
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $3.73 Now $3.71 −0.40% settles Nov 17
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $3.77 Now $3.71 −1.59% settles Nov 17
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $3.77 Now $3.71 −1.59% settles Nov 17
- Nov 12, 20264d ago 425 Neutral 3/10 Entry $3.77 to $3.71 Now $3.71 −1.59% ▼ −1.59% +0.32% vs SPY
- Nov 12, 20264d ago 8-K Neutral 3/10 Entry $3.77 to $3.71 Now $3.71 −1.59% ▼ −1.59% +0.32% vs SPY
- Nov 5, 202612d ago EFFECT Neutral 4/10 Entry $3.68 to $3.70 Now $3.71 +0.82% ▲ +0.54% +0.23% vs SPY
- Nov 3, 202613d ago S-4/A Neutral 5/10 Entry $3.74 to $3.77 Now $3.71 −0.80% ▲ +0.80% −0.85% vs SPY
- Oct 28, 202619d ago SC 13G/A Neutral 2/10 Entry $3.75 to $3.77 Now $3.71 −1.07% ▲ +0.53% +0.92% vs SPY
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $3.75 to $3.77 Now $3.71 −1.07% ▲ +0.53% +0.92% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers